Vistogard is owned by Wellstat Therap.
Vistogard contains Uridine Triacetate.
Vistogard has a total of 2 drug patents out of which 0 drug patents have expired.
Vistogard was authorised for market use on 11 December, 2015.
Vistogard is available in granule;oral dosage forms.
Vistogard can be used as emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adverse reactions within 96 hours.
The generics of Vistogard are possible to be released after 17 August, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6258795||WELLSTAT THERAP||Acylated uridine and cytidine and uses thereof|| |
(a month from now)
|US7776838||WELLSTAT THERAP||Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides|| |
(4 years from now)
|Orphan Drug Exclusivity (ODE)||Dec 11, 2022|
Drugs and Companies using URIDINE TRIACETATE ingredient
Market Authorisation Date: 11 December, 2015
Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic